Market Overview:
The global lipid disorder treatment market is expected to grow at a CAGR of 5.8% from 2018 to 2030. The market growth is attributed to the increasing prevalence of lipid disorders, rising geriatric population, and technological advancements in the field of lipid disorder treatment. Based on type, the global lipid disorder treatment market is segmented into atorvastatin, fluvastatin, rosuvastatin, simvastatin, pravastatin and other drugs. Based on application, the global lipid disorder treatment market is segmented into hospitals, clinics and others. Geographically, the global Lipid Disorder Treatment Market is segmented into North America (U.S., Canada), Latin America (Mexico), Europe (Germany France Italy Spain U.K.), Asia Pacific (China Japan India South Korea) Middle East & Africa(Saudi Arabia UAE Qatar South Africa).
Product Definition:
Lipid Disorder Treatment is a type of medical treatment that is used to help people who have problems with their lipid levels. Lipid levels are important because they help to regulate the body's metabolism and can play a role in preventing heart disease.
Atorvastatin:
Atorvastatin is a lipase inhibitor. It works by decreasing the amount of fat and cholesterol that are made in the liver.
Fluvastatin:
Flavonoids are naturally occurring plant pigments that exhibit cardioprotective, antioxidant, and anti-inflammatory properties. The most commonly used flavonoid is quercetin found in various plants including rutin, apigenin, luteolin and kaempferol. Flavonoids have been the subject of extensive research over the past few years with respect to their potential therapeutic applications for treating cardiovascular diseases.
Application Insights:
The others application segment held the largest share of over 60.0% in 2017. The major applications of other drugs include pharmacies and retail stores, which cater to the demand for generic medicines. Increasing awareness among individuals regarding their health and wellness is expected to be a key driving factor for market growth during the forecast period.
Hospitals were estimated as the largest revenue-generating centers owing to factors such as advanced healthcare facilities and highly skilled medical personnel at these hospitals who are capable of handling complex cases related to lipid disorders efficiently.
Regional Analysis:
North America dominated the global market in 2017 owing to the presence of key players, favorable government initiatives, and increasing prevalence of cardiovascular diseases & diabetes. The U.S., which is at the forefront of this region, accounted for a revenue share of over 80% in 2017 due to high consumer awareness about treatment options and easy availability of these drugs through various channels including online vendors.
Asia Pacific is expected to witness lucrative growth during the forecast period owing to rising disposable income levels coupled with improving healthcare infrastructure & affordability issues faced by patients in this region. China led Asia Pacific with a revenue share exceeding 20% in 2017 due to growing demand for low-cost generic drugs as well as high unmet clinical needs pertaining health conditions that require proper diagnosis and treatment using modern medication methods supported by effective medical insurance systems facilitating access for all socioeconomic strata groups thereby boosting regional growth prospects during the forecast period from 2018 - 2030 (estimated).
Growth Factors:
- Increasing prevalence of lipid disorders
- Growing awareness about the benefits of lipid disorder treatment
- Rising demand for better and more effective treatments for lipid disorders
- Technological advancements in the field of lipid disorder treatment
- Growing number of research and development activities focused on developing new and better treatments for lipid disorders
Scope Of The Report
Report Attributes
Report Details
Report Title
Lipid Disorder Treatment Market Research Report
By Type
Atorvastatin, Fluvastatin, Rosuvastatin, Simvastatin, Pravastatin, Other Drugs
By Application
Hospitals, Clinics, Others
By Companies
Teva Pharmaceuticals, Mylan Pharmaceuticals, Kowa Pharmaceuticals, Glenmark Pharmaceuticals, Sun Pharmaceuticals, Wockhardt
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
143
Number of Tables & Figures
101
Customization Available
Yes, the report can be customized as per your need.
Global Lipid Disorder Treatment Market Report Segments:
The global Lipid Disorder Treatment market is segmented on the basis of:
Types
Atorvastatin, Fluvastatin, Rosuvastatin, Simvastatin, Pravastatin, Other Drugs
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Teva Pharmaceuticals
- Mylan Pharmaceuticals
- Kowa Pharmaceuticals
- Glenmark Pharmaceuticals
- Sun Pharmaceuticals
- Wockhardt
Highlights of The Lipid Disorder Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Atorvastatin
- Fluvastatin
- Rosuvastatin
- Simvastatin
- Pravastatin
- Other Drugs
- By Application:
- Hospitals
- Clinics
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Lipid Disorder Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
There is no one-size-fits-all answer to this question, as the best lipid disorder treatment will vary depending on the individual's specific condition and symptoms. However, some common treatments for lipid disorders include lifestyle changes (such as diet and exercise), medication therapy (including statins), and surgery.
Some of the major companies in the lipid disorder treatment market are Teva Pharmaceuticals, Mylan Pharmaceuticals, Kowa Pharmaceuticals, Glenmark Pharmaceuticals, Sun Pharmaceuticals, Wockhardt.
The lipid disorder treatment market is expected to register a CAGR of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Lipid Disorder Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Lipid Disorder Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Lipid Disorder Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Lipid Disorder Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Lipid Disorder Treatment Market Size & Forecast, 2020-2028
4.5.1 Lipid Disorder Treatment Market Size and Y-o-Y Growth
4.5.2 Lipid Disorder Treatment Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Atorvastatin
5.2.2 Fluvastatin
5.2.3 Rosuvastatin
5.2.4 Simvastatin
5.2.5 Pravastatin
5.2.6 Other Drugs
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Lipid Disorder Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Lipid Disorder Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Atorvastatin
9.6.2 Fluvastatin
9.6.3 Rosuvastatin
9.6.4 Simvastatin
9.6.5 Pravastatin
9.6.6 Other Drugs
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Atorvastatin
10.6.2 Fluvastatin
10.6.3 Rosuvastatin
10.6.4 Simvastatin
10.6.5 Pravastatin
10.6.6 Other Drugs
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Atorvastatin
11.6.2 Fluvastatin
11.6.3 Rosuvastatin
11.6.4 Simvastatin
11.6.5 Pravastatin
11.6.6 Other Drugs
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Atorvastatin
12.6.2 Fluvastatin
12.6.3 Rosuvastatin
12.6.4 Simvastatin
12.6.5 Pravastatin
12.6.6 Other Drugs
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Atorvastatin
13.6.2 Fluvastatin
13.6.3 Rosuvastatin
13.6.4 Simvastatin
13.6.5 Pravastatin
13.6.6 Other Drugs
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Lipid Disorder Treatment Market: Competitive Dashboard
14.2 Global Lipid Disorder Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Teva Pharmaceuticals
14.3.2 Mylan Pharmaceuticals
14.3.3 Kowa Pharmaceuticals
14.3.4 Glenmark Pharmaceuticals
14.3.5 Sun Pharmaceuticals
14.3.6 Wockhardt
